ERBB2 and breast cancer: Apart from its adverse cardiotoxic effect, prolonged treatment with trastuzumab generates an acquired resistance toward the drug, giving rise to a trastuzumab-resistant highly aggressive, metastatic, and invasive subline of HER2-positive breast cancer cells [113,114,115].